Le Lézard
Classified in: Health, Science and technology, Covid-19 virus
Subjects: Event, Product/Service, Trade Show

AmerisourceBergen Hosts First-Ever ThinkLive Trade Virtual Conference


Today, AmerisourceBergen kicked off its first-ever ThinkLive Trade virtual event, a three-day online summit geared toward brand, specialty and generic manufacturers. The COVID-19 pandemic has tested the resilience of the healthcare industry and required all pharmaceutical supply chain stakeholders to act and respond with unwavering commitment and creativity. Over the three-day event, AmerisourceBergen will address current industry challenges and how the company will collaborate with partners, manufacturers and customers to drive supply chain sophistication and optimize the development and delivery of pharmaceuticals and healthcare products in the future.

"There has never been a better time to convene our associates and manufacturer partners to discuss medication accessibility, healthcare efficiency and supply chain reliability," said Sun Park, Executive Vice President and Group Chief Financial Officer, Pharmaceutical Distribution & Strategic Global Sourcing at AmerisourceBergen. "2020 has proved that strong relationships across the pharmaceutical supply chain are absolutely critical, for our industry and the health of our country. Even though we will all participate remotely, ThinkLive Trade will be an opportunity for us to get grounded in the year ahead and have meaningful dialogue with our partners about how we can collaborate to advance patient access and healthcare delivery during this pandemic and beyond."

Conference programming will include remarks from AmerisourceBergen Chairman, President & CEO Steve Collis, dynamic panel discussions, presentations, live Q&A, awards, virtual networking sessions and more. Content and meetings will be facilitated through AmerisourceBergen's new event platform, AmerisourceBergen Live.

On the first day of the summit, attendees will hear directly from AmerisourceBergen executives on the state of the industry, opportunities for healthcare to evolve as a result of lessons learned during COVID-19 and where opportunities exist with technology and innovation to drive efficiencies across the supply chain. Day two of ThinkLive Trade will focus on the intersection of healthcare and politics, and the final day of the conference will feature outside perspectives from Wall Street analysts, as well as timely discussions on global generics, specialty pharmaceutical products, biosimilars, consumer trends and more.

AmerisourceBergen will also host ThinkLive Commercialization in February 2021. The event will bring together emerging biotech and biopharma leaders to discuss the latest in launch strategies across different therapeutic categories.

For more in-depth perspectives from ThinkLive Trade and AmerisourceBergen on policy and market trends, supply chain resilience, medication access, innovative therapies and more, please visit: https://www.fiercepharma.com/topic/supply-chain

About AmerisourceBergen

AmerisourceBergen provides pharmaceutical products, value-driving services and business solutions that improve access to care. Tens of thousands of healthcare providers, veterinary practices and livestock producers trust us as their partner in the pharmaceutical supply chain. Global manufacturers depend on us for services that drive commercial success for their products. Through our daily work ? and powered by our 22,000 associates ? we are united in our responsibility to create healthier futures. AmerisourceBergen is ranked #10 on the Fortune 500, with more than $175 billion in annual revenue. The company is headquartered in Valley Forge, Pa. and has a presence in 50+ countries. Learn more at amerisourcebergen.com


These press releases may also interest you

at 18:05
GlycoMimetics' product candidate uproleselan ? when added to a combination therapy of venetoclax and a hypomethylating agent (HMA) ? was shown today in an oral presentation to break chemoresistance by dramatically and significantly reducing tumor...

at 18:00
Quanta X Technology, the parent company of QuantaDose, CEO Katie Webb suggests, "Anyone in Santa's shoes gifting a UVC device to a friend or family member needs to make sure the UV-C device is real, and they also need to understand the potential...

at 17:00
63% response rate in patients treated with the highest reported dose Among all patients responding to treatment, 95% experienced a very good partial response or better; among responding patients with ?6 months of follow-up, 83% have ongoing responses...

at 16:30
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today updated results from an ongoing Phase 1 first-in-human dose escalation study (NCT03145181) of teclistamab (JNJ-64007957) for the treatment of relapsed or refractory multiple...

at 15:30
Gracell Biotechnologies Inc. ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced an interim readout to evaluate the...

at 15:05
bluebird bio, Inc. today presented updated long-term efficacy and safety results reflecting up to six years of data for betibeglogene autotemcel gene therapy (beti-cel; formerly LentiGlobintm for ?-thalassemia) in patients with transfusion-dependent...



News published on 27 october 2020 at 13:35 and distributed by: